Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Eric M, Maiese"'
Autor:
Rafael Fonseca, Saad Z. Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, Eric M. Maiese, Sandhya Nair, Ravi Potluri, Peter M. Voorhees
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities.
Externí odkaz:
https://doaj.org/article/0f1b33e8ad784fecbc53fa0b5af5dc8f
Autor:
Shiv Saidha, Judith Bell, Sydney Harold, Jose Marcano Belisario, Emma Hawe, Qiujun Shao, Kerri Wyse, Eric M. Maiese
Publikováno v:
Neurological Sciences. 44:1515-1532
Objective To exp lore changes in immunoglobulin (Ig) levels for people with relapsing-multiple sclerosis (RMS) treated with ocrelizumab or ofatumumab and the relationship between Ig levels and infections. Methods A systematic literature review (SLR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29362841cd255508927bcba2067ecc18
https://doi.org/10.1007/s10072-022-06582-y
https://doi.org/10.1007/s10072-022-06582-y
Autor:
Andreas, Nikolaou, Cosmina, Hogea, Yevgeniy, Samyshkin, Eric M, Maiese, Leah, Sansbury, Mustafa, Oguz, Javier, Cid-Ruzafa, Ritika, Kapoor, Feng, Wang
Publikováno v:
Value in Health. 25:1977-1985
Estimates on the distribution of patients with multiple myeloma (MM) by line of therapy (LOT) are scarce and get outdated quickly as new treatments become available. The objective of this study was to estimate the number of patients with MM by LOT an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f9cfa14917be5e9f29ed02fb7576ec
https://doi.org/10.1016/j.jval.2022.05.011
https://doi.org/10.1016/j.jval.2022.05.011
Autor:
Enrique Alvarez, Kavita V. Nair, Hiangkiat Tan, Kapil Rathi, Nicole B. Gabler, Eric M. Maiese, Chinmay Deshpande, Qiujun Shao
Evaluate the real-world costs over two years and costs by site of care for ocrelizumab (OCR), natalizumab (NTZ), and alemtuzumab (ATZ) in patients with multiple sclerosis (MS). This retrospective study used HealthCore Integrated Research Database and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e453f159fa6ca849e2ae8ab7be799da5
Autor:
Eric M. Maiese, Karin Travers, Lydia Walder, Carol Hawkes, Chloe Spalding, Jinan Liu, Jean Hurteau
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1377-1387
BACKGROUND: Ovarian cancer (OC) is the fifth leading cause of cancer death in women and has the highest mortality rate of gynecological cancers. Niraparib was recently approved by the FDA for the maintenance treatment of adult patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc592d3db5109e74cced80c1c77b91f
https://doi.org/10.18553/jmcp.2021.27.10.1377
https://doi.org/10.18553/jmcp.2021.27.10.1377
Autor:
Marie-Hélène Lafeuille, Fuad Paramasivam, Melody Chang, Hela Romdhani, Lucio Gordan, Eric M Maiese, Caroline McKay
Publikováno v:
Drugs-Real World Outcomes
Background Some institutions have implemented a daratumumab intravenous rapid-infusion protocol in which patients with multiple myeloma (MM) receive their third and subsequent infusions within ~ 90 min instead of ≥ 3 h. Objective This study sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e3e041ad17171617ab2bcbc17931b28
https://doi.org/10.1007/s40801-020-00226-3
https://doi.org/10.1007/s40801-020-00226-3
Autor:
Laurie Batchelder, Stephanie Philpott, Victoria Divino, Natalie Boytsov, Eric M Maiese, Cosmina Hogea, Trudy Buckingham, Chi-Chang Chen, Ana Maria Rodriguez
Publikováno v:
Future oncology (London, England). 18(25)
Aim: This study aimed to assess physician preferences for later lines (third to fifth) of therapy in patients with relapsed/refractory multiple myeloma (RRMM) in the USA. Materials & methods: Factors relevant to physicians' treatment preferences for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251d7385ed7606155305b2104d4fd60c
https://pubmed.ncbi.nlm.nih.gov/35801416
https://pubmed.ncbi.nlm.nih.gov/35801416
Autor:
Peter M. Voorhees, Jianming He, Sarah Cote, Ravi Potluri, Mary Slavcev, Annette Lam, Eric M Maiese, Maneesha Mehra, Sandhya Nair, Jon Ukropec, Rafael Fonseca, Saad Z. Usmani
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2dac1dcf5ce7f602352ba295257abb
http://link.springer.com/article/10.1186/s12885-020-07503-y
http://link.springer.com/article/10.1186/s12885-020-07503-y
Autor:
Saad Z. Usmani, Annette Lam, Bareng A. S. Nonyane, Eric M Maiese, Shaji Kumar, Brian G.M. Durie, Thierry Facon, Rachel Kobos, Eric M. Ammann
Publikováno v:
American Journal of Hematology
Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c40a46b0818776bb922a95f30fee5d
https://doi.org/10.1002/ajh.25963
https://doi.org/10.1002/ajh.25963
Autor:
Joseph J. Sabatino, Kristen Mittl, William Rowles, Colin R. Zamecnik, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Jessa Alexander, Kira Mcpolin, PeiXi Chen, Chinmay Deshpande, Kerri Wyse, Eric M. Maiese, Michael R. Wilson, Scott S. Zamvil, Riley Bove
Publikováno v:
Multiple Sclerosis and Related Disorders. 70:104484
BackgroundAdequate response to the SARS-CoV-2 vaccine represents an important treatment goal in caring for patients with multiple sclerosis (MS) during the ongoing COVID-19 pandemic. Previous data so far have demonstrated lower spike-specific IgG res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f15528018fa0ee3e92a721fd9a77a1c5
https://doi.org/10.1016/j.msard.2022.104484
https://doi.org/10.1016/j.msard.2022.104484